1. Home
  2. Directory
  3. California
  4. Ridgecrest
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1023012739

DR. DANIEL H MALLORY O.D.
Prescription History 1023012739
Optometrist in Ridgecrest, CA

NPI Status: Active since June 09, 2005

Contact Information

1409 N NORMA ST
RIDGECREST, CA
ZIP 93555
Phone: (760) 446-5555
Fax: (790) 446-2905

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. DANIEL H MALLORY O.D., an active Optometrist specialist practicing in Ridgecrest, CA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 221 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 140 claims alone.

Medication Index

B
L
T
No matching medications currently found on file.

Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Optometry
Provider Metrics Summary
Total Claims 14
30-Day Fills 25.8
Days Supply 764
CA State Average Benchmarks
Peer Average Claims78.0
Peer Average 30-Day Fills160.1
Peer Average Days Supply4,677
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.1% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,134.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$295.32

State Avg Cost Per Claim

$43.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 140
30-Day Fills 220.8
Days Supply 6,181
CA State Average Benchmarks
Peer Average Claims159.0
Peer Average 30-Day Fills301.1
Peer Average Days Supply8,658
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,461.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.58

State Avg Cost Per Claim

$21.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Lumigan

Generic Formulation: BimatoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.9
Days Supply 349
CA State Average Benchmarks
Peer Average Claims82.0
Peer Average 30-Day Fills135.5
Peer Average Days Supply3,851
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 84.1% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,864.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$297.26

State Avg Cost Per Claim

$432.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Optometry
Provider Metrics Summary
Total Claims 54
30-Day Fills 89.2
Days Supply 2,574
CA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills41.8
Peer Average Days Supply1,318
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 134.8% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $680.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.60

State Avg Cost Per Claim

$450.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. DANIEL H MALLORY O.D. provides transparency into local medical care patterns within Ridgecrest, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.